
SureNano Science's Novel Triple Agonist Peptide GEP-44 Could Reshape GLP-1 Market
SureNano Science Ltd. is featured in a BioMedWire editorial highlighting its subsidiary GlucaPharm's GEP-44, a triple agonist peptide with improved tolerability and potential non-injectable delivery, addressing the growing GLP-1 therapeutic market for obesity and metabolic diseases.
Read full story
























